High-yield overview
Most Common Primary Bone Cancer
Distal Femur Most Common (50%)Location
Adolescents 10-20 (Peak)Age
Sunburst + Codman TriangleX-ray
60-70% (Localized Disease)Survival
Osteosarcoma Subtypes
Conventional (75%)
PatternHigh-grade intramedullary, produces osteoid.
TreatmentNeoadjuvant + Surgery + Adjuvant chemo
Telangiectatic (10%)
PatternLytic, hemorrhagic, mimics ABC.
TreatmentSame protocol as conventional
Parosteal (4%)
PatternLow-grade surface tumor.
TreatmentWide resection only - no chemo
Periosteal (2%)
PatternIntermediate-grade surface.
TreatmentMay need adjuvant chemo
Critical Must-Knows
- Distal Femur: Most common location (50%), then proximal tibia (25%).
- Bimodal Age: Adolescents (primary) and over 60 (secondary - Paget's).
- Sunburst: Spiculated periosteal reaction - pathognomonic radiographic sign.
- Codman Triangle: Elevated periosteum at tumor margin.
- MAP Protocol: Methotrexate (high-dose), Adriamycin, cisPlatin.
- Histologic Response: Over 90% necrosis = good prognosis (75-80% survival).
Clinical Pearls
- "Distal femur most common primary bone cancer location
- "Sunburst + Codman triangle = osteosarcoma until proven otherwise
- "Neoadjuvant chemo BEFORE surgery - treats micrometastases
- "Over 90% necrosis = good response and better prognosis
- "Biopsy tract must be excised with specimen - plan with surgeon
Clinical Imaging
Imaging Gallery
Critical Treatment Principle
Osteosarcoma treatment REQUIRES CHEMOTHERAPY.
- Surgery alone results in 80% recurrence (micrometastases at presentation).
- Neoadjuvant chemotherapy: Shrinks tumor, treats micrometastases, allows histologic assessment.
- Adjuvant chemotherapy: Completes treatment, improves survival from 20% to 60-70%.
- Exception: Parosteal osteosarcoma (low-grade surface) - wide resection only.
At a Glance Table
| Feature | Details |
|---|---|
| Definition | Primary malignant bone tumor producing osteoid by malignant cells |
| Incidence | 3-4 per million per year (most common primary bone cancer in adolescents) |
| Peak Age | Bimodal: 10-20 years (primary), over 60 (secondary - Paget's) |
| Sex Ratio | Male to Female = 1.5:1 |
| Most Common Location | Distal femur (50%), proximal tibia (25%), proximal humerus (10%) |
| Classic Triad | Pain + Mass + Restricted ROM |
| Pathognomonic X-ray | Sunburst periosteal reaction + Codman triangle |
| Treatment Protocol | Neoadjuvant chemo → Wide resection → Adjuvant chemo |
| 5-Year Survival | 60-70% localized, 20-30% metastatic at presentation |
| Key Prognostic Factor | Histologic necrosis (over 90% = good response) |
Mnemonic Cards
Mnemonic
DPHFOsteosarcoma Sites - DPHF
| D | Distal femur 50% - Most common location around knee |
| P | Proximal tibia 25% - Second most common, also knee |
| H | Humerus (proximal) 10% - Third most common site |
| F | Flat bones Pelvis, skull in older patients |
| D | Distal femur 50% - Most common location around knee | H | Humerus (proximal) 10% - Third most common site |
| P | Proximal tibia 25% - Second most common, also knee | F | Flat bones Pelvis, skull in older patients |
Hook:DPHF - 'Down Past the Hip to Flat' - Remember location distribution by frequency.
Mnemonic
SCAMRadiographic Signs - SCAM
| S | Sunburst Spiculated periosteal reaction (pathognomonic) |
| C | Codman triangle Elevated periosteum at tumor margin |
| A | Aggressive Wide zone of transition, cortical destruction |
| M | Mixed Mixed lytic and sclerotic (osteoid production) |
| S | Sunburst Spiculated periosteal reaction (pathognomonic) | A | Aggressive Wide zone of transition, cortical destruction |
| C | Codman triangle Elevated periosteum at tumor margin | M | Mixed Mixed lytic and sclerotic (osteoid production) |
Hook:SCAM the X-ray - Classic aggressive bone tumor appearance on radiographs.
Mnemonic
MAP CMAP Chemotherapy
| M | Methotrexate High-dose with leucovorin rescue |
| A | Adriamycin Doxorubicin - cardiotoxicity limit |
| P | cisPlatin Platinum agent - nephrotoxicity |
| M | Methotrexate High-dose with leucovorin rescue |
| A | Adriamycin Doxorubicin - cardiotoxicity limit |
| P | cisPlatin Platinum agent - nephrotoxicity |
Hook:MAP your treatment - All 3 drugs needed for optimal survival in osteosarcoma.
Mnemonic
GTMEnneking Staging - GTM
| G | Grade G1 (low) vs G2 (high grade) |
| T | Tumor site T1 (intra) vs T2 (extracompartmental) |
| M | Metastases M0 (none) vs M1 (present) |
| G | Grade G1 (low) vs G2 (high grade) |
| T | Tumor site T1 (intra) vs T2 (extracompartmental) |
| M | Metastases M0 (none) vs M1 (present) |
Hook:GTM staging - Grade, Tumor site, Mets determine prognosis and margin requirements.
Overview/Epidemiology
Osteosarcoma is the most common primary malignant bone tumor, characterized by direct formation of osteoid or immature bone by malignant mesenchymal cells.
Epidemiology
Incidence
- 3-4 per million per year
- 400 new cases in USA annually
- Most common in adolescents
- Second peak over 60 years
Risk Factors
- Prior radiation therapy
- Paget's disease (1% transform)
- Li-Fraumeni syndrome (p53)
- Hereditary retinoblastoma (Rb1)
- Rothmund-Thomson syndrome
Location Distribution
- Distal femur: 50%
- Proximal tibia: 25%
- Proximal humerus: 10%
- Other long bones: 15%
- Metaphyseal predilection
Bimodal Age Distribution
| Peak | Age Range | Characteristics | Association |
|---|---|---|---|
| Primary Peak | 10-20 years | Rapid skeletal growth | Metaphyseal location, conventional type |
| Secondary Peak | Over 60 years | Paget's sarcoma | Axial skeleton, poor prognosis |
Clinical Pearl
Paget's Sarcoma: Secondary osteosarcoma in Paget's disease occurs in 1% of patients. Presents with sudden increase in pain, rapid enlargement, or rising alkaline phosphatase in known Paget's. Very poor prognosis (5-year survival under 10%).
Anatomy/Biomechanics
Anatomic Considerations for Tumor Location
Metaphyseal Predilection:
- Osteosarcoma arises from primitive mesenchymal bone-forming cells
- Metaphyses have highest osteoblastic activity during growth
- Rich blood supply to metaphyses facilitates tumor growth
- Growth plate initially acts as barrier to epiphyseal extension
Compartmental Anatomy
Tumor Extension Patterns:
| Direction | Barrier | Clinical Significance |
|---|---|---|
| Intramedullary | Cortical bone | Skip lesions possible - MRI entire bone |
| Extraosseous | Soft tissue planes | Neurovascular involvement risk |
| Transphyseal | Growth plate | Less effective barrier than previously thought |
| Intra-articular | Joint capsule | Rare but indicates Stage IIB/III |
Neurovascular Relationships
Distal Femur (Most Common Site):
- Popliteal artery/vein: Posterior to femur, at risk with posterior extension
- Femoral artery/vein: In Hunter's canal - anterior/medial approach consideration
- Sciatic nerve: Posterolateral - divides to tibial and common peroneal above knee
Proximal Tibia:
- Popliteal vessels: Posterior, trifurcate below knee
- Anterior tibial vessels: Pass through interosseous membrane
- Common peroneal nerve: Wraps around fibular neck - high risk
Classification Systems
WHO Histologic Classification:
Osteosarcoma Subtypes by Grade and Location
| Subtype | Grade | Location | Chemotherapy |
|---|---|---|---|
| High | Intramedullary | Yes - MAP protocol | |
| High | Intramedullary | Yes - Same as conventional | |
| High | Intramedullary | Yes - May add Ewing's protocol | |
| Low | Surface (posterior femur) | No - Wide resection only | |
| Intermediate | Surface (diaphysis) | Consider adjuvant | |
| High | Surface | Yes - Full protocol |
Key point: Conventional osteosarcoma (75%) requires full chemotherapy protocol.
Clinical Presentation
History
Primary Symptoms
- Pain: Progressive, worse at night
- Initially activity-related
- Becomes constant
- May wake from sleep
- NSAIDs initially helpful
Mass/Swelling
- Develops over weeks-months
- May be warm to touch
- Firm, fixed to bone
- Skin changes rare
- Visible deformity late
Red Flags
- Pathological fracture (10%)
- Weight loss (late)
- Night sweats (rare)
- Respiratory symptoms (mets)
- Duration under 6 months typical
Physical Examination
Systematic Assessment:
-
Inspection:
- Swelling/mass location
- Skin changes (rare, late)
- Muscle wasting (adjacent)
- Limb length (if growth plate involved)
-
Palpation:
- Mass characteristics: Firm, fixed to bone, tender
- Warmth (increased vascularity)
- Range of motion (reduced if near joint)
- Lymph nodes (rarely involved - under 3%)
-
Neurovascular:
- Pulses (rarely compromised)
- Sensation (late involvement)
- Motor function
- Compartment tension
Pathological Fracture
10% of osteosarcomas present with pathological fracture. This does NOT automatically preclude limb salvage but:
- Creates surgical challenge (contamination of fracture hematoma)
- May require modified chemotherapy timing
- Still achieves similar survival with careful planning
Differential Diagnosis
| Diagnosis | Key Distinguishing Features |
|---|---|
| Ewing Sarcoma | Diaphyseal, permeative, onion-skin periosteal, smaller cell |
| Chondrosarcoma | Older patients (40-60), axial, chondroid matrix (arcs/rings) |
| Giant Cell Tumor | Epiphyseal, eccentrically lytic, no matrix |
| Osteomyelitis | Systemic symptoms, sequestrum, involucrum |
| Stress Fracture | Transverse, no soft tissue mass, healing callus |
| Aneurysmal Bone Cyst | Eccentric, expansile, fluid levels on MRI |
Investigations
Imaging Protocol
First-Line Investigation - Essential Characteristics:
-
Location:
- Metaphyseal (most common)
- Eccentric or central
-
Matrix:
- Osteoid production (cloud-like density)
- "Cumulus cloud" appearance
- Dense sclerotic areas
-
Periosteal Reaction:
- Sunburst/Spiculated: Pathognomonic
- Codman Triangle: Elevated periosteum at margins
- Indicates aggressive behavior
-
Margins:
- Permeative/moth-eaten (aggressive)
- Wide zone of transition
- Cortical destruction
-
Soft Tissue:
- Extraosseous mass
- May show calcification
These findings together create the classic "aggressive bone lesion" appearance.
Biopsy Principles
Biopsy Planning - CRITICAL
The biopsy is the MOST IMPORTANT step in diagnosis:
- MUST be planned with definitive surgeon
- Wrong approach contaminates compartments
- Biopsy tract excised with specimen
- Violating these principles may necessitate amputation
Biopsy Technique:
| Approach | Pros | Cons | Indication |
|---|---|---|---|
| Core Needle | Less contamination, outpatient | May miss diagnosis (sampling) | Preferred in most centers |
| Open Incisional | More tissue, higher accuracy | More contamination | If core non-diagnostic |
| Excisional | Diagnostic + therapeutic | Contraindicated | Never for suspected osteosarcoma |
Biopsy Rules:
- Longitudinal incision along planned resection
- Avoid contaminating neurovascular structures
- Through muscle (not between compartments)
- Meticulous hemostasis
- Mark biopsy site for excision
Management Algorithm
Algorithm
Standard Treatment Pathway:
DIAGNOSIS CONFIRMED
↓
STAGING (MRI, CT Chest, Bone Scan)
↓
┌───────────────────┐
│ NEOADJUVANT CHEMO │ → 8-12 weeks MAP protocol
│ (Pre-operative) │
└─────────┬─────────┘
↓
RESTAGING
↓
┌───────────────────┐
│ WIDE RESECTION │ → Limb salvage (80-90%) or Amputation
│ ± Recon │
└─────────┬─────────┘
↓
HISTOLOGIC ASSESSMENT
(% tumor necrosis)
↓
┌───────────────────┐
│ ADJUVANT CHEMO │ → Continue/modify based on response
│ (Post-operative) │
└───────────────────┘
Key point: Surgery is performed AFTER neoadjuvant chemotherapy to assess histologic response.
Non-Operative Management
Chemotherapy Protocol
Mnemonic
MAP CMAP Chemotherapy
| M | Methotrexate High-dose with leucovorin rescue |
| A | Adriamycin Doxorubicin - cardiotoxicity limit |
| P | cisPlatin Platinum agent - nephrotoxicity |
| M | Methotrexate High-dose with leucovorin rescue |
| A | Adriamycin Doxorubicin - cardiotoxicity limit |
| P | cisPlatin Platinum agent - nephrotoxicity |
Hook:MAP your treatment - all 3 drugs needed for optimal survival.
Neoadjuvant Chemotherapy (Pre-operative):
- Duration: 8-12 weeks (2-4 cycles)
- Purpose: Shrink tumor, treat micrometastases, assess response
- Response assessment: Tumor shrinkage on imaging (not reliable)
Adjuvant Chemotherapy (Post-operative):
- Duration: 12-29 weeks additional
- Total treatment: Approximately 1 year
- Modifications based on histologic response
Chemotherapy Toxicities
| Agent | Major Toxicity | Monitoring | Management |
|---|---|---|---|
| Methotrexate | Mucositis, nephrotoxicity, hepatotoxicity | Levels, renal function | Leucovorin rescue, hydration |
| Doxorubicin | Cardiotoxicity (dose-dependent) | Echo/MUGA | Lifetime dose limit 450mg/m² |
| Cisplatin | Nephrotoxicity, ototoxicity, neuropathy | Cr, audiometry | Hydration, dose adjustment |
Clinical Pearl
Doxorubicin Cardiotoxicity: Cumulative dose-dependent. Lifetime limit typically 450mg/m². Echo/MUGA before each cycle. Irreversible cardiomyopathy if exceeded.
Indications for Chemotherapy
| Subtype | Neoadjuvant | Adjuvant | Notes |
|---|---|---|---|
| Conventional | Yes | Yes | Standard MAP protocol |
| Telangiectatic | Yes | Yes | Same as conventional |
| Parosteal (Low-grade) | No | No | Wide resection only |
| Periosteal | Consider | Consider | Case-by-case decision |
| High-grade Surface | Yes | Yes | Full protocol |
Surgical Technique
Surgical Principles
Margin Requirements:
- Wide Margin: Minimum 1-2cm of bone beyond tumor
- Cuff of Normal Tissue: Must include reactive zone
- Biopsy Tract: Excise with specimen
- Skip Lesions: Must be included in resection
Limb Salvage Options
Modular Metal Replacement:
Indications:
- Most common reconstruction
- Distal femur, proximal tibia, proximal humerus
- Allows early mobilization
Advantages:
- Immediate stability
- Early weight-bearing
- No donor site morbidity
Disadvantages:
- Mechanical failure (5-10 year revision)
- Infection (5-15%)
- Aseptic loosening
- Limited lifespan in young patients
Growing Prostheses:
- For skeletally immature patients
- Non-invasive lengthening available
- Multiple lengthening procedures required
Endoprosthesis remains the gold standard for most limb salvage reconstructions.
Amputation Considerations
When Amputation is Indicated:
- Neurovascular encasement (not reconstructable)
- Massive soft tissue involvement
- Poor response to chemotherapy with progression
- Pathological fracture with contamination
- Patient preference
- Infection precluding salvage
- Expected non-functional limb
Amputation Levels:
- Above-knee for distal femur tumors
- Hip disarticulation for proximal femur
- Forequarter for proximal humerus (rarely needed)
Clinical Pearl
Survival Equal: Multiple studies confirm limb salvage and amputation have equivalent oncologic outcomes when appropriate margins achieved. Limb salvage preferred when feasible due to better function and quality of life.
Complications
Chemotherapy Complications
| Complication | Agent | Incidence | Prevention/Management |
|---|---|---|---|
| Cardiotoxicity | Doxorubicin | 5-10% | Dose limit 450mg/m², serial Echo |
| Nephrotoxicity | Cisplatin, MTX | 10-20% | Hydration, dose adjustment |
| Ototoxicity | Cisplatin | 10-30% | Audiometry, dose modification |
| Mucositis | MTX | 40-60% | Leucovorin rescue, supportive care |
| Myelosuppression | All agents | Universal | G-CSF, transfusions |
| Secondary Malignancy | All agents | 2-5% | Long-term surveillance |
Surgical Complications
Early Complications
- Wound infection/dehiscence (10-15%)
- Flap necrosis
- Deep vein thrombosis
- Neurovascular injury
- Periprosthetic fracture
Late Complications
- Aseptic loosening (30% at 10 years)
- Prosthesis failure/breakage
- Infection (5-15% lifetime)
- Leg length discrepancy
- Amputation (10-15% conversion)
Allograft Specific
- Non-union (15-30%)
- Fracture (15-20%)
- Resorption
- Disease transmission (rare)
- Infection (10-15%)
Local Recurrence
Risk Factors:
- Inadequate margins
- Poor histologic response
- Skip lesion missed
- Pathological fracture
- Biopsy tract violation
Management:
- Re-staging (local + systemic)
- Further resection if possible
- Amputation if no salvage option
- Chemotherapy if not previously given
- Prognosis worse (30-40% survival)
Postoperative Care
Immediate Postoperative Period
Day 0-7:
- ICU/HDU for 24-48 hours (major surgery)
- DVT prophylaxis (mechanical + chemical)
- Wound assessment (skin flaps, drain output)
- Pain management (multimodal analgesia)
- Limb elevation
Week 1-6:
- Physiotherapy: ROM exercises
- Weight-bearing: Depends on reconstruction
- Endoprosthesis: Touch weight-bearing → progressive
- Allograft: Protected weight-bearing 6-12 weeks
- Wound care: Watch for infection/dehiscence
- Chemotherapy: Resumes when wound healed (usually week 3-4)
Rehabilitation Protocol
| Phase | Timeline | Goals | Activities |
|---|---|---|---|
| Acute | 0-6 weeks | Wound healing, ROM | Bed exercises, transfer training |
| Intermediate | 6-12 weeks | Strength, progressive WB | Gait training, strengthening |
| Advanced | 3-6 months | Full function | Sport-specific training |
| Maintenance | Ongoing | Monitor function | Activity modification as needed |
Follow-up Surveillance
Year 1-2:
- Every 3 months: Clinical exam, chest X-ray
- Every 6 months: CT chest, local imaging
Year 3-5:
- Every 6 months: Clinical exam, chest X-ray
- Annual: CT chest
Beyond 5 years:
- Annual clinical and radiographic review
- Late recurrence possible (rare after 10 years)
- Monitor for late effects of chemotherapy
Outcomes/Prognosis
Survival Rates
| Disease Status | 5-Year Survival | Notes |
|---|---|---|
| Localized Disease | 60-70% | Majority of presentations |
| Metastatic at Diagnosis | 20-30% | 15-20% have lung mets at presentation |
| Good Response (over 90% necrosis) | 75-80% | Strongest prognostic factor |
| Poor Response (under 90% necrosis) | 50-55% | Still benefits from adjuvant chemo |
| Local Recurrence | 30-40% | Depends on resectability |
Prognostic Factors
Favorable vs Unfavorable Prognostic Factors
| Factor | Favorable | Unfavorable |
|---|---|---|
| Over 90% necrosis | Under 90% necrosis | |
| Localized disease | Metastatic at diagnosis | |
| Extremity | Axial skeleton, pelvis | |
| Under 8cm | Over 8cm, skip lesions | |
| Normal | Elevated | |
| Wide/negative | Marginal/positive |
Mnemonic
SMARTOsteosarcoma Prognosis
| S | Size Under 8cm better |
| M | Metastases Absence = better |
| A | ALP Normal = better |
| R | Response Over 90% necrosis = best |
| T | Type/Site Extremity, conventional = better |
| S | Size Under 8cm better | R | Response Over 90% necrosis = best |
| M | Metastases Absence = better | T | Type/Site Extremity, conventional = better |
| A | ALP Normal = better |
Hook:SMART prognosis assessment.
Functional Outcomes
Limb Salvage:
- MSTS functional score: 70-85%
- Most return to normal daily activities
- Competitive sports: Limited/modified
- Prosthesis revision: Expected at 10-15 years
Amputation:
- Prosthetic fitting: 2-3 months post-op
- Above-knee: 60-70% MSTS score
- Quality of life: Similar to limb salvage
- Energy expenditure: Higher for ambulation
Evidence Base
Landmark
Rosen G et al - Preoperative chemotherapy (T10 protocol)
Key Findings:
- 57 extremity osteosarcomas treated with preoperative high-dose methotrexate, doxorubicin and BCD
- Histologic response (over 90% necrosis) used to tailor postoperative chemotherapy
- Poor responders salvaged by switching regimen: 32 of 35 (91%) remained disease-free short-term
- Established neoadjuvant chemotherapy and histologic response as the modern treatment paradigm
Clinical Implication: Chemotherapy is essential and histologic response guides prognosis - surgery alone is inadequate.
Source: Cancer 1982
Level I
EURAMOS-1 (Marina N et al) - MAPIE vs MAP for poor responders
Key Findings:
- Largest osteosarcoma trial: 2260 registered, 618 poor responders randomised (MAP vs MAPIE)
- Adding ifosfamide and etoposide (MAPIE) did NOT improve event-free survival (HR 0.98)
- MAPIE increased grade 3-4 toxicity (febrile neutropenia, non-haematological events)
- Defines standard postoperative MAP as standard of care even for poor responders
Clinical Implication: Poor responders still receive standard adjuvant MAP - intensification adds toxicity without survival benefit.
Source: Lancet Oncol 2016
Level III
Simon MA et al - Limb-salvage vs amputation, distal femur osteosarcoma
Key Findings:
- Multi-institutional retrospective study of 227 distal femur osteosarcomas
- No difference in survival between limb-sparing surgery, above-knee amputation, or hip disarticulation (p=0.8)
- Local recurrence and metastasis rates comparable across groups
- Overall 5-year survival 55%; disease-free survival 42%
Clinical Implication: Limb salvage is preferred when feasible - oncologic outcomes equal those of amputation.
Source: JBJS Am 1986
Level III
Bacci G et al - Serum alkaline phosphatase as a prognostic factor
Key Findings:
- 560 extremity high-grade osteosarcomas treated with neoadjuvant chemotherapy at Rizzoli
- On multivariate analysis only two factors independently predicted event-free survival
- Pre-treatment serum alkaline phosphatase (p=0.002) and chemotherapy-induced necrosis (p=0.0001)
- 5-year event-free survival 60%, overall survival 68%
Clinical Implication: Elevated alkaline phosphatase is an independent adverse prognostic marker - stratify and counsel accordingly.
Source: Oncol Rep 2002
Level III
Mankin HJ et al - The hazards of biopsy, revisited (MSTS)
Key Findings:
- Musculoskeletal Tumor Society survey of 597 sarcoma biopsies across 21 institutions
- Diagnostic error rate 17.8%; biopsy problems altered management in 19.3% of patients
- Errors and complications two to twelve times higher when biopsy done at referring (non-treatment) centre
- 18 patients underwent unnecessary amputation due to biopsy-related problems
Clinical Implication: Biopsy must be performed at (or planned with) the definitive sarcoma centre - poor biopsy can cost the limb.
Source: JBJS Am 1996
Level IV
Wafa H, Grimer R, Jeys L et al - Total humeral endoprosthesis
Key Findings:
- 34 patients (15 osteosarcoma) after whole-bone resection and endoprosthetic reconstruction
- Cumulative 10-year implant survival 90% (Kaplan-Meier)
- Periprosthetic infection was the most common surgical complication
- Mean MSTS functional score 83% in disease survivors
Clinical Implication: Endoprosthetic limb salvage gives durable function but counsel patients on infection and long-term revision risk.
Source: Clin Orthop Relat Res 2015
Controversies & Areas of Uncertainty
| Question | Current position | Why it remains unsettled |
|---|---|---|
| Can we improve the poor responder? | Standard postoperative MAP remains standard of care | EURAMOS-1 showed adding ifosfamide/etoposide (MAPIE) gave no survival benefit and more toxicity; no regimen has reliably rescued poor responders |
| Role of mifamurtide (L-MTP-PE) | Added to chemotherapy in some guidelines (eg EMA approval); not universally adopted (eg not FDA-approved) | INT-0133 reported a survival signal of borderline statistical interpretation; benefit and cost-effectiveness still debated |
| Margin width for "wide" resection | Negative margin with a cuff of normal tissue; exact millimetre threshold not fixed | Necrotic, chemotherapy-treated tumour blurs the reactive zone; response quality may matter more than absolute distance |
| Pathological fracture and limb salvage | No longer an absolute contraindication if good chemotherapy response and clear margins | Older data suggested higher local recurrence; modern series show comparable outcomes with careful selection |
| Extent of staging (PET-CT vs conventional) | CT chest plus bone scan remain core; PET-CT increasingly used | PET-CT response (SUV change) is prognostic but has not replaced histologic necrosis as the reference standard |
| Surveillance imaging intensity | Regular chest imaging and local review for at least 5 years | Optimal frequency, modality (CXR vs CT) and radiation/cost trade-offs are not standardised internationally |
Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
CLINICAL SCENARIOStandard
Distal Femur Mass in Adolescent
CLINICAL PROMPT
"A 14-year-old boy presents with 3 months of worsening right knee pain. X-ray shows an aggressive metaphyseal lesion in the distal femur with a sunburst periosteal reaction and Codman triangle. How do you manage this patient?"
PRACTICAL APPROACH
This presentation is highly suspicious for osteosarcoma - the combination of adolescent age, metaphyseal location, sunburst periosteal reaction, and Codman triangle is classic.
Immediate Management:
- Staging workup: MRI of entire femur (skip lesions), CT chest (lung mets), whole body bone scan
- Laboratory: FBC, U&E, LFTs, alkaline phosphatase, LDH
- Biopsy: Planned with definitive surgeon - longitudinal incision through planned resection approach, core needle preferred, meticulous hemostasis
Treatment Protocol (if confirmed):
- Neoadjuvant chemotherapy: MAP protocol (high-dose Methotrexate, Adriamycin, cisPlatin) for 8-12 weeks
- Restaging: Assess response before surgery
- Wide resection: Limb salvage if feasible (endoprosthesis most common), minimum 2cm bone margin, excise biopsy tract
- Histologic assessment: Percent necrosis (over 90% = good response)
- Adjuvant chemotherapy: Complete treatment protocol
Prognosis: Localized disease has 60-70% 5-year survival. Good histologic response improves this to 75-80%.
KEY CLINICAL POINTS
Classic presentation: Adolescent + metaphyseal + sunburst + Codman
Biopsy MUST be planned with definitive surgeon
MRI entire femur for skip lesions
Neoadjuvant chemo essential before surgery
Over 90% necrosis indicates good response
COMMON PITFALLS
Biopsy through wrong approach contaminating compartments
Surgery without chemotherapy
Missing skip lesions by not imaging entire bone
Forgetting to excise biopsy tract
FURTHER QUESTIONS
"What chemotherapy agents are used?"
"What are the surgical reconstruction options?"
"What defines a good histologic response?"
CLINICAL SCENARIOStandard
Parosteal Osteosarcoma
CLINICAL PROMPT
"A 35-year-old woman has a slowly enlarging mass on the posterior aspect of her distal femur for 2 years. X-ray shows a densely ossified surface lesion attached to the posterior cortex. Biopsy confirms low-grade parosteal osteosarcoma. How does management differ from conventional osteosarcoma?"
PRACTICAL APPROACH
Parosteal osteosarcoma is a low-grade surface variant with distinctly different management from conventional osteosarcoma.
Key Differences:
- No chemotherapy required - low-grade tumor with minimal metastatic potential
- Wide surgical resection alone is curative in most cases
- Excellent prognosis: 90-95% 5-year survival
Surgical Considerations:
- Wide resection with adequate margins (can be marginal in some cases for function)
- May allow joint preservation if not involving articular surface
- Posterior approach for posterior distal femur lesions
- Reconstruction depends on residual bone stock
Important Caveats:
- Dedifferentiation can occur (10-15%) - high-grade areas require chemotherapy
- Biopsy must adequately sample for high-grade component
- If dedifferentiated, treat as conventional osteosarcoma
Surveillance: Regular imaging to detect local recurrence or dedifferentiation.
KEY CLINICAL POINTS
Low-grade surface tumor - NO chemotherapy needed
Wide resection alone is curative (90-95% survival)
Watch for dedifferentiation (requires full treatment)
Posterior distal femur classic location
Densely ossified appearance on X-ray
COMMON PITFALLS
Giving unnecessary chemotherapy
Missing dedifferentiated component on biopsy
Inadequate margins due to favorable histology
FURTHER QUESTIONS
"How does periosteal osteosarcoma differ?"
"What percentage dedifferentiate?"
"How do you counsel regarding prognosis?"
CLINICAL SCENARIOStandard
Metastatic Osteosarcoma
CLINICAL PROMPT
"A 16-year-old presents with a distal femur osteosarcoma. Staging CT chest reveals 3 pulmonary nodules consistent with metastatic disease. How does this change your management approach?"
PRACTICAL APPROACH
Metastatic osteosarcoma at diagnosis occurs in 15-20% of patients and significantly impacts prognosis (5-year survival 20-30%).
Key Management Principles:
- Treatment is NOT palliative - still aim for cure in selected patients
- Complete resection of ALL disease (primary + metastases) improves survival
Modified Treatment Approach:
- Neoadjuvant chemotherapy: Standard MAP protocol (may be intensified)
- Assess response: Both primary and metastatic disease
- Surgical resection:
- Primary tumor: Wide resection with limb salvage if feasible
- Pulmonary metastases: Thoracotomy/VATS for complete metastasectomy
- Both can be done simultaneously or staged
- Adjuvant chemotherapy: Complete treatment protocol
Favorable Features for Metastatic Disease:
- Unilateral lung involvement
- Small number of metastases (under 4-5)
- Good response to chemotherapy
- Complete surgical resection achievable
Prognosis: If complete resection of all disease achieved, 5-year survival can reach 30-40%. Incomplete resection has poor outcomes.
KEY CLINICAL POINTS
15-20% present with pulmonary mets
Still aim for cure - NOT palliative
Complete resection of ALL disease essential
Thoracotomy for pulmonary metastasectomy
5-year survival 20-30% (better if complete resection)
COMMON PITFALLS
Treating as palliative - should aim for cure
Failing to resect pulmonary metastases
Proceeding without adequate staging (PET/bone scan)
FURTHER QUESTIONS
"What if pulmonary mets appear during treatment?"
"What if mets are bilateral?"
"What is the role of stereotactic radiotherapy?"
MCQ Practice Points
MCQ Pearl 1: Location
Q: What is the most common site for osteosarcoma? A: Distal femur (50%), followed by proximal tibia (25%), proximal humerus (10%). Remember: "Around the knee" in adolescents.
MCQ Pearl 2: X-ray Findings
Q: What are the pathognomonic radiographic features of osteosarcoma? A: Sunburst periosteal reaction and Codman triangle. Also look for: permeative destruction, osteoid matrix (cloud-like), soft tissue mass.
MCQ Pearl 3: Chemotherapy Protocol
Q: What is the standard chemotherapy regimen for osteosarcoma? A: MAP - high-dose Methotrexate (with leucovorin rescue), Adriamycin (doxorubicin), cisPlatin.
MCQ Pearl 4: Histologic Response
Q: What defines a good histologic response in osteosarcoma? A: Over 90% tumor necrosis in resected specimen. This is the strongest prognostic factor (5-year survival 75-80% vs 50-55% for poor response).
MCQ Pearl 5: Parosteal Exception
Q: Which osteosarcoma subtype does NOT require chemotherapy? A: Parosteal osteosarcoma - low-grade surface tumor treated with wide resection alone. 90-95% 5-year survival. Watch for dedifferentiation.
Common MCQ Scenarios
| Scenario | Key Answer Point |
|---|---|
| Adolescent + metaphyseal + sunburst | Osteosarcoma - biopsy with surgeon |
| Densely ossified posterior femur surface | Parosteal osteosarcoma - no chemo |
| Under 90% necrosis post-neoadjuvant | Continue standard adjuvant chemo |
| Skip lesion on MRI | Include in resection, not contraindication to limb salvage |
| Pathological fracture | Still attempt limb salvage with modified approach |
| Elevated ALP/LDH | Poor prognostic factor |
| Paget's disease + sudden pain | Suspect secondary osteosarcoma |
Guidelines, Registries & Global Practice
Global Epidemiology
- Incidence approximately 3-4 per million per year worldwide, the most common primary bone sarcoma of childhood and adolescence
- Bimodal distribution: a dominant adolescent peak (skeletal growth spurt) and a smaller secondary peak over 60 (often Paget-associated or radiation-induced), the latter carrying a markedly worse prognosis
- Outcomes plateaued internationally since the 1980s: 60-70% 5-year survival for localised disease, 20-30% for metastatic disease at presentation, with no major survival gain from chemotherapy intensification (EURAMOS-1)
Major Guidelines Side by Side
| Body (region) | Core recommendations |
|---|---|
| NCCN (US) | MAP backbone; wide resection with limb salvage where margins achievable; metastasectomy for resectable lung disease |
| ESMO / EURACAN (Europe) | Treat in reference sarcoma centres; neoadjuvant MAP, surgery, response-adapted continuation; no benefit from adding ifosfamide/etoposide for poor responders |
| BOA / BSG (UK) | Mandatory referral to a recognised bone-sarcoma centre before biopsy; biopsy by (or directed by) the operating surgeon |
| AO Foundation / general | Plan biopsy along the definitive incision; excise the biopsy tract en bloc with the specimen |
Registry and Network Evidence
- Cooperative groups (COSS, COG, EOI, SSG) feeding the EURAMOS collaboration provide the strongest randomised evidence base
- Bone-tumour endoprosthesis outcome data are pooled through specialist-centre series (eg Birmingham/Royal Orthopaedic Hospital) rather than national joint registries, which exclude tumour implants
- International tumour banking and biobanking underpin ongoing molecular and trial work
High- vs Limited-Resource Practice Variation
- High-resource settings: centralised multidisciplinary sarcoma units, neoadjuvant MAP, limb salvage in 80-90%, growing/expandable endoprostheses for skeletally immature children
- Limited-resource settings: later presentation with larger tumours and higher rates of pathological fracture, limited access to high-dose methotrexate monitoring, higher reliance on amputation and on biologic reconstruction (allograft, recycled autograft) where implants are unaffordable
Clinical Pearl
Universal principle: Osteosarcoma must be managed by a specialist multidisciplinary sarcoma team, and biopsy must be planned with the definitive surgeon. Referral BEFORE biopsy is the single most important system-level safeguard worldwide.
Summary Points
High-Yield Take-Home Messages
- Osteosarcoma = Most common primary bone cancer in adolescents, defined by osteoid production
- Distal femur most common site (50%), "around the knee" in growing skeleton
- Sunburst + Codman triangle on X-ray = osteosarcoma until proven otherwise
- Biopsy MUST be planned with definitive surgeon - wrong approach contaminates compartments
- MRI entire bone - skip lesions occur in 1-5%, change surgical planning
- Neoadjuvant chemotherapy essential - MAP protocol (Methotrexate, Adriamycin, Platinum)
- Histologic response is strongest prognostic factor - over 90% necrosis = good response
- Limb salvage in 80-90% - equivalent survival to amputation
- Parosteal = exception - low-grade surface tumor, wide resection alone, no chemo
- Metastatic disease still aim for cure - complete resection of ALL disease improves survival
Self-Assessment Quiz
OSTEOSARCOMA
Clinical summary
CLINICAL FEATURES
- •Distal femur most common (50%)
- •Bimodal: adolescents + over 60 (Paget's)
- •Sunburst + Codman triangle on X-ray
- •Pain worse at night, progressive swelling
STAGING WORKUP
- •MRI entire bone (skip lesions)
- •CT chest (lung mets - 80% of distant disease)
- •Bone scan (systemic staging)
- •Biopsy planned with definitive surgeon
TREATMENT PROTOCOL
- •Neoadjuvant: MAP chemo 8-12 weeks
- •Wide resection (limb salvage 80-90%)
- •Assess histologic necrosis (over 90% = good)
- •Adjuvant chemotherapy to complete
SUBTYPES
- •Conventional (75%): High-grade, needs chemo
- •Telangiectatic: Lytic, same treatment
- •Parosteal: Low-grade, NO chemo needed
- •Periosteal: Intermediate, consider chemo
PROGNOSIS
- •Localized: 60-70% 5-year survival
- •Metastatic: 20-30% survival
- •Over 90% necrosis: 75-80% survival
- •Under 90% necrosis: 50-55% survival
EXAM TRAPS
- •Biopsy through wrong approach
- •Surgery without chemotherapy
- •Missing skip lesions (MRI entire bone)
- •Giving chemo for parosteal type